Kurma Partners

Adcytherix is a clinical-stage biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs) to address high unmet medical needs in oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to tackle cancers resistant to current therapies.

Avidicure is pioneering an entirely new triple agonistic antibody modality, 'Actibody', designed to safely deliver targeted and potent monotherapy for patients, with broad applicability in oncology and autoimmune diseases.

Nuevocor is a clinical-stage biotechnology company focused on developing novel therapies for patients suffering from life-threatening cardiomyopathies, particularly through a mechanobiology-centered approach.

SciRhom GmbH is a pioneering biotech enterprise focused on developing first-in-class humanized antibodies against iRhom2 for the treatment of autoimmune diseases, including rheumatoid arthritis and inflammatory bowel disease.

Arkhn Assistant is a generative AI solution designed for healthcare, automating the writing of medical reports and providing quick access to patient information, thereby reducing administrative workload for healthcare professionals.

Omnidoc is a medical collaboration platform that connects healthcare professionals and organizations to exchange opinions, coordinate care, and make informed decisions throughout the patient journey.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Early-stage drug-discovery company creator that originates companies in-house, incubates single ultra-orphan and rare-disease bets for years and millions, and commits to very long development timelines.

5AM Ventures focuses exclusively on the earliest stages of life sciences companies, often investing at or before seed stage and operating an in-house company-creation engine called the 4:59 Initiative. The firm combines hands-on involvement with partners taking short-term operating roles and remaining deeply engaged throughout a company's life, alongside systematic focus on capital efficiency and faster realizations.

Founded in 2002, +ND invests in disruptive technologies spanning life, physical, and data sciences, prioritizing opportunities driven by scientific convergence.

Creates and seeds about half its portfolio companies from in-house discovery labs (Ridgeline in Basel, Highline in New York), seeding them with tens of millions and re-running key experiments, importing big-pharma discipline into venture-backed biotech.